BLEND TERMINAL // BPC-157 + TB-500
BPC-157 TB-500 is a two-peptide research blend, decoded channel by channel here.
Two distinct peptides, two largely non-overlapping mechanisms, and a forum that calls the pairing synergy. Every constituent finding is read against its own study — and the combination's human data reads zero.
Two peptides, one name, no single molecule
BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair pairing — not a single chemical entity. The "Wolverine" blend co-formulates two distinct synthetic peptides. BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide, sequence GEPPPGKPADDAGLV, ~1419.5 Da, derived from a partial sequence of a protein found in human gastric juice [1]. TB-500 is a synthetic N-acetylated heptapeptide, Ac-LKKTETQ, ~889 Da, corresponding to residues 17-23 — the actin-binding motif — of the 43-residue protein Thymosin Beta-4 [3].
The blend has no single molecular weight, no CAS number, and no shared structure. Those values describe its two constituents, and the entire story of the pairing is that the two act through separate routes. BPC-157 supplies a local cytoprotective and pro-angiogenic signal — across rodent models it up-regulates VEGFR2 and modulates the nitric-oxide system [2]. TB-500 supplies an intracellular actin-sequestration signal that governs cell migration, the cytoskeletal half of the proposed pairing [3]. The forums call the combination synergy. The published record calls it two mechanisms that have never been tested together in a controlled study.
That single fact frames everything else on this site. There are no controlled clinical trials of the BPC-157 + TB-500 combination, and the most relevant 2025 systematic review of BPC-157 — 36 studies, only one of them human — does not mention TB-500 at all [9]. The constituent data are real and, in places, striking; the combination data are absent. We hold those two truths side by side rather than blurring them.
This site reads each constituent's literature against its own studies, flags every claim by evidence tier, and surfaces the data gap before the promise. Start with why BPC-157 is paired with TB-500, then check the latest BPC-157 TB-500 research and Wolverine legal status and FDA 503A category.
BPC-157 and TB-500: the two peptides in the blend
BPC-157 and TB-500 are paired for complementary roles. BPC-157 is the cytoprotective and angiogenic leg: across rodent models it up-regulates VEGFR2, modulates the nitric-oxide system, and promotes tendocyte and fibroblast outgrowth. In a fully transected rat Achilles tendon, 10 μg/kg improved load-to-failure, collagen organization, and tendon integrity versus untreated controls [1]. Its pro-angiogenic action runs through VEGFR2 up-regulation and internalization with downstream Akt-eNOS signaling [2].
TB-500 is the cytoskeletal leg. Its LKKTETQ helix binds monomeric G-actin 1:1; crystallography of a Thymosin Beta-4-actin complex showed the motif sequesters the monomer by capping both ends, the structural basis for the actin dynamics that drive cell migration [3]. One caveat doubles in the blend: most efficacy data attributed to "TB-500" were generated with full-length Thymosin Beta-4 (~4963 Da), not the 7-mer [4].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV), the cytoprotective and angiogenic component [1]. TB-500 is a synthetic Ac-LKKTETQ heptapeptide from the actin-binding region of Thymosin Beta-4, the cytoskeletal and cell-migration component [3]. The blend pairs the two; it is not one molecule.
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-mer gastric-juice-derived peptide acting locally via VEGFR2 and eNOS [2]. TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [3]. Different size, different origin, different mechanism — paired in the blend for complementary, not overlapping, effects.
The "Wolverine" peptide blend explained
The wolverine peptide name is a marketing and forum label, not a chemical one — and its search volume is partly conflated with the comic-book character. As applied to peptides it refers to the BPC-157 + TB-500 pairing, framed as a regenerative "stack." There is no approved Wolverine drug, no standardized composition, and no validated ratio. Commercial vials are commonly labeled with a combined per-vial mass (for example, 10 mg BPC-157 + 10 mg TB-500), but that ratio is a packaging convention, not a clinically validated dose.
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 with TB-500, discussed as a tissue-repair stack. It is not a single chemical entity and not an approved product; the two peptides are distinct synthetic molecules co-marketed under one brand label.
The "Wolverine" stack terminology
"Stack" and "blend" are used interchangeably in research-peptide communities for the BPC-157 + TB-500 pairing. Neither term implies a tested formulation. A wolverine peptide stack is the same two peptides under the same brand framing — BPC-157 as the cytoprotective leg and TB-500 as the actin-migration leg.
What is the BPC-157 TB-500 stack terminology?
"Stack" is community shorthand for combining two or more research peptides. The BPC-157 TB-500 stack is the BPC-157 + TB-500 pairing. The word describes a combination practice, not a validated product or a defined dose, and no controlled trial has tested the stack.
What does "wolverine peptide stack" contain?
The wolverine peptide stack contains the same two constituents: BPC-157, a 15-amino-acid pentadecapeptide [1], and TB-500, the Ac-LKKTETQ fragment of Thymosin Beta-4 [3]. The naming is branded; the contents are unchanged from the BPC-157 + TB-500 blend.
Open the effects file
The rev3 corpus adds a plain-language BPC-157 TB-500 effects and safety page beside the component research. Community reports remain labeled as reports, while cited blend and component cautions occupy a separate channel.